Research programme: protein degradation-based therapeutics - Arvinas

Drug Profile

Research programme: protein degradation-based therapeutics - Arvinas

Alternative Names: ARCC-29; ARV-110; ARV-378; ARV-771; BET-PROTAC ARV-771; Hydrophobic Tagging small molecules - Arvinas; HyT small molecules - Arvinas; PROTAC ARV-771; PROTAC ARV-825; PROTACs - Arvinas; Protein-targeting chimeric molecules - Arvinas; Proteolysis Targeting Chimeric molecules - Arvinas

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arvinas
  • Developer Arvinas; Yale University
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor degradation enhancers; BRD4-protein-inhibitors; Bromodomain and extraterminal domain protein inhibitors; Estrogen-receptor-alpha-degradation-enhancers; Proteasome stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Haematological malignancies; Prostate cancer; Solid tumours
  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 05 Jan 2018 Arvinas plans a clinical trial for ARV 378 in Breast cancer
  • 04 Jan 2018 Arvinas enters into a collaboration and license agreement with Pfizer for development of small molecule therapeutics
  • 08 Dec 2017 Pharmacodynamics data from preclinical trials in Breast cancer released by Arvinas
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top